{"id":"NCT00688688","sponsor":"Astellas Pharma Inc","briefTitle":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","officialTitle":"A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04-25","primaryCompletion":"2010-05-06","completion":"2010-05-06","firstPosted":"2008-06-03","resultsPosted":"2012-10-19","lastUpdate":"2024-11-20"},"enrollment":2792,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Bladder, Overactive"],"interventions":[{"type":"DRUG","name":"Mirabegron","otherNames":["Myrbetriq","YM178"]},{"type":"DRUG","name":"Tolterodine","otherNames":[]},{"type":"DRUG","name":"Placebo to Mirabegron","otherNames":[]},{"type":"DRUG","name":"Placebo to Tolterodine","otherNames":[]}],"arms":[{"label":"Mirabegron 50 mg","type":"EXPERIMENTAL"},{"label":"Mirabegron 100 mg","type":"EXPERIMENTAL"},{"label":"Tolterodine ER 4 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.","primaryOutcome":{"measure":"Number of Participants With and Severity of Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From the first dose of double-blind study drug up until 30 days after the last dose of study drug, up to 13 months.","effectByArm":[{"arm":"Mirabegron 50 mg","deltaMin":222,"sd":null},{"arm":"Mirabegron 100 mg","deltaMin":240,"sd":null},{"arm":"Tolterodine ER 4 mg","deltaMin":251,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":308,"countries":["United States","Australia","Austria","Belarus","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Hungary","Iceland","Ireland","Italy","Latvia","Lithuania","Netherlands","Norway","Poland","Portugal","Romania","Russia","Slovakia","South Africa","Spain","Sweden","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["23195283"],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=25"]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":812},"commonTop":["Hypertension","Urinary tract infection","Dry mouth"]}}